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ABSTRACT
Introduction: Reductions in the prevalence of hepatitis B virus (HBV) infection and carriage, 
decreases in liver cancer incidence, and changes in patterns of liver dysfunctions are described 
after hepatitis B vaccination. Methods: We conducted a population-based seroprevalence 
study aimed at estimating the HBV prevalence and risk of infection in the rural area of Lábrea 
following nineteen years of HBV vaccination. Results: Half of the subjects showed total 
anti-HBc of 52.1% (95% CI 49.6-54.7). The HBsAg prevalence was 6.2% (95% CI 5.1-7.6). 
Multivariate analysis showed an inverse association between HBV infection and vaccination 
(OR 0.62; 95% CI 0.44-0.87). HBsAg remained independently associated with past hepatitis 
(OR 2.44; 95% CI 1.52-3.89) and inversely to vaccination (OR 0.43; 95% CI 0.27-0.69). The 
prevalence of HBeAg among HBsAg-positive individuals was 20.4% (95% CI 12.8-30.1), 
with the positive subjects having a median age of 11 years (1-46) p=0.0003. Conclusions: 
We demonstrate that HBV infection is still an important public health issue and that HBV 
vaccination could have had better impact on HBV epidemiology. If we extrapolate these findings 
to other rural areas in the Brazilian Amazon, we can predict that the sources of chronic infected 
patients remain a challenge. Future studies are needed regarding clinical aspects, molecular 
epidemiology, surveillance of acute cases, and risk groups.
Keywords: HBV. Hepatitis B. Prevalence. Vaccination. Epidemiology.
RESUMO
Introdução: Reduções nas taxas de prevalência de infecção pelo vírus da hepatite B 
(VHB) e de portadores, incidência de câncer de fígado e mudança nos padrões de doenças 
hepáticas são descritos, depois da introdução da vacinação contra hepatite B. Métodos: Foi 
conduzido um estudo de soro prevalência de base populacional, com o objetivo de estimar a 
prevalência do VHB e fatores de risco de infecção na área rural de Lábrea, depois de 19 anos de 
introdução da vacinação contra hepatite B. Resultados: Metade dos indivíduos investigados 
mostrou reatividade ao anti-HBc total, 52,1% (IC 95% 49,6-54,7). A prevalência do HBsAg 
foi 6,2% (IC 95% 5,1-7,6). Análises multivariadas mostrou associação inversa da infecção 
pelo VHB e vacinação (OR 0,62; IC 95% 0<44-0,87). A presença do HBsAg permaneceu 
independentemente associada com o passado de hepatite (OR 2,44; IC 95% 1,52-3,89) e 
inversamente associado a história de vacinação (OR 0,43; IC 95% 0,27-0,69). A prevalência do 
HBeAg, entre os HBsAg positivos foi 20,4%  (IC95% 12,8-30,1), tendo em média os indivíduos 
positivos 11 anos de idade (1-46) p=0,0003. Conclusões: Foi demonstrado que o VHB é ainda 
um importante problema de saúde publica, e que a vacinação contra o VHB poderia ter tido 
um impacto maior na epidemiologia do VHB na região. Se esses achados forem extrapolados 
para outras regiões rurais da Amazônia brasileira, podemos predizer que a fonte de pacientes 
crônicos é ainda um desafio a ser vencido. Estudos futuros devem focar os aspectos clínicos, 
a epidemiologia molecular, vigilância de casos agudos e grupos de risco.
Palavras-chaves: HBV. Hepatite B. Prevalência. Vacinação. Epidemiologia.
Prevalence of hepatitis B virus infection and carriage after nineteen 
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Prevalência da infecção e de portadores do vírus da hepatite B, após 19 anos do programa de 
vacinação na Amazônia ocidental Brasileira
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Hepatitis B virus (HBV) infection has a global 
public health impact, with some 300 million chronic 
carriers worldwide1. Clinical importance is associated 
with both fatal acute infection and chronic diseases 
(chronic hepatitis, liver cirrhosis, and liver cancer).
High prevalence rates have been described in 
Southeast Asia2, Africa3, the Pacific Islands4, the 
Amazon region5-6, and Alaska7. In these areas, the 
virus is primarily transmitted perinatally from 
infected mothers, horizontally in early childhood8-10, 
or by blood exposure as a result of cultural practice11.
In the Brazilian Amazon, prevalence rates of 
70% for past infection and 15% for surface antigen 
(HBsAg) carriage have been described12. Outbreaks 
of acute fatal hepatitis used to be very common in 
small rural villages, with a very high case fatality 
rate associated with hepatitis delta virus (HDV) 
infection of HBsAg carriers12-13.
Reductions in the prevalence of HBsAg infection 
and carriage, decreases in liver cancer incidence, 
and even changes in patterns of liver dysfunctions 
have been described after the implementation of 
hepatitis B vaccination programs in highly endemic 
countries14-17.
We conducted a population-based cross-
sectional survey aimed at estimating the HBV 
serological marker prevalence and risk of infection 
in the rural zone of Lábrea county, Western Brazilian 
Amazon, following nineteen years of implementation 
of a hepatitis B vaccination program in the region.
METHODS
This is a population-based seroprevalence 
study of HBV infection. Lábrea is located in the 
Southwestern Brazilian Amazon (Figure 1), has an 
estimated rural population of 10,000, and was the 
first place in Brazil to receive the hepatitis B vaccine 
during the first national vaccination campaign in 
October 1989.
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FIGURE 1 - Map of the study area.
The region was first reached during the colonization period by 
those collecting forest products. In the nineteenth century, during the 
rubber boom, a huge number of nordestinos, those born in Northeast 
Brazil, resettled in the area to work at the natural rubber plantations. 
Currently, the villages are small, formed by those who remained 
after rubber extraction declined. The economy is still based on the 
exploitation of natural resources, such as seasonal agriculture at 
the half-year flooded banks of the Purus River, timber production, 
growing Brazil nuts, and raising livestock, with the products traded 
locally. The socioeconomic conditions are very poor, and the annual 
per capita income is around US$1,000.
The target population consisted of all individuals living in the 
villages that compose the Lábrea County, along the Purus River. 
Villages were first randomly selected from a list from the Malaria 
Control Program, assuring that we had covered all the provincial 
geographical areas along the banks of the Purus River. Then, the 
research team randomly selected households in each village. The 
villages were visited from March 2005 to April 2006, during three 
major twenty-day expeditions and a few one-day trips to the villages 
near the town of Lábrea.
After signing the formal consent to participate, each individual 
filled out a questionnaire. A 10mL blood sample was taken from 
each of those present during the investigation; some family members 
were included later during our stay at the location because they were 
absent at the time of the visit.
The sample size was estimated using the official rural population 
census18, resulting in an estimated HBsAg prevalence of 6.4%19, 
a design factor of 2, ±2% precision, and 95% confidence level, which 
yielded a minimum sample of 1,009 individuals.
The serum samples were stored at -200C locally before being 
flown to Manaus, where they were analyzed by enzyme-linked 
immunosorbent assay (ELISA). All sera were tested for quantitative 
anti-HBs and total anti-HBc; those reactive to total anti-HBc and 
negative for anti-HBs were tested for HBsAg, and those found 
reactive were tested for HBeAg and anti-HBe using a commercial kit 
(DiaSorin S.p.A., Saluggia, Italy). The test procedures followed the 
manufacturer’s recommendations and were performed automatically 
at the laboratory facilities of the virology unit of Fundação de Medicina 
Tropical do Amazonas.
Epi Info version 3.3.220was used in data handling and sample size 
calculation; the explanatory variables included gender, age group, 
vaccination against hepatitis B, and personal antecedent of clinical 
hepatitis or jaundice. The study population was stratified by two-year 
groups for the first four years of life, then by 5-year increments up 
to the age of 19, and those 20 years or older, which comprised the 
population at risk of HBV infection before the implementation of 
hepatitis B vaccination.
The prevalence rates and corresponding 95% confidence 
intervals (95% CI) of HBV infection and carriage were estimated 
taking into account the study design. Logistic regression was used 
to calculate the crude ORs and 95% CIs. A final multiple logistic 
regression model including all study variables was used to control 
for confounding using Stata/IC 10.021.
Ethical considerations
This study was reviewed and approved by the Research Ethics 
Committee of the Dr. Heitor Vieira Dourado Tropical Medicine Foundation 
(FMT-HVD), Manaus, Amazonas, Brazil (no1775/2006 CEP/FMT).
This study included 1,510 individuals from 298 families 
selected in 54 visited villages. The infection and carriage rates 
varied significantly between villages, from as low as 0% in Realeza 
(07º35’52.8”S/66º13’29.2”O) to as high as 37.2% in Madeirinho 
(07º34’19.1”S/65º26’31.4”O).
Nevertheless, with regard to HBsAg prevalence, the great 
majority of the villages with positive subjects showed rates varying 
from high to moderate endemic patterns, as shown by the prevalence 
rates of 10.7% in Limeira (07º43’13.4”S/66º42’33.7”W) and 6.5% 
in Praia do Buraco (07º17’48.6”S/64º58’28.3”W).
Half of the sample (52.1%) showed serological markers of past 
HBV infection (95% CI 49.6-54.7). HBV infection was strongly 
associated with increasing age (Chi-square for linear trend=551.28, 
p<0.001) and positively associated with past history of clinical 
hepatitis (OR 2.31(95% CI 1.74-3.06) p<0.001); it was also inversely 
related to HBV vaccination (OR 0.33 (95% CI 0.25-0.43) p<0.001) 
(Table 1).
The current infection (HBsAg+) prevalence was 6.2% (95% CI 5.1-7.6) 
and also increased significantly with age (Chi-square for linear 
trend=48.21, p<0.001). HBsAg had been present since very early 
ages, with 2% of those aged up to four years testing positive. However, 
the rates reached moderate patterns among adolescents (5.6%, 95% 
CI 4.31-6.89) and were as high as 10% (95% CI 9.34-10.9) within 
the cohort of those aged 20 years or more (Table 2).
HBV current infection also showed a positive statistical 
association with past history of clinical hepatitis (OR 3.17 (95% CI 
2.04-4.90) p<0.001) and was inversely related to HBV vaccination 
(OR 0.33 (95% CI 0.21-0.56) p<0.001) (Table 2).
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DISCUSSION
After fitting a multiple logistic regression model including all the 
study variables, the association of HBV infection with past history 
of clinical hepatitis disappeared (OR 1.06 (95% CI 0.75-1.49) 
p=0.74). Nevertheless, we still detected an inverse association with 
HBV vaccination (OR 0.62 (95% CI 0.44-0.87) p=0.005) (Table 1).
Hepatitis B virus carriage remained independently associated with 
past history of hepatitis (OR 2.44 (95% CI 1.52-3.89) p<0.001) and 
inversely related to HBV vaccination (OR 0.43 (95% CI 0.27-0.69) 
p<0.001) (Table 2).
The prevalence of HBeAg among HBsAg-positive individuals was 
20.4% (19∕93) (95% CI 12.8-30.1), with the positive subjects having 
a median age of 11 years (1-46) (p=0.0003) (Kruskal-Wallis test).
To the best of our knowledge, this is the first population-based 
seroprevalence study of HBV infection in the rural areas of the 
Western Brazilian Amazon, within the defined geographical limits, 
TABLE 1 - Hepatitis B infection (anti-HBc reactive) prevalence and associated variables, Rural Lábrea municipality, Western Amazon, Brazil, 2007.
 Subjects                 Positive subjects   Adjusted 
Variable (n) n % (95% CI) Crude OR (95% CI) p-value OR (95% CI)* p-value
Total sample 1,510 787 52.1 (49.6-54.7) — — — —
Age group      
<2 136 24 17.6 (16.1-19.1) 1   1 <0.001**
3-4 114 14 12.3 (10.8-14.0) 0.65 (0.32-1.33)  0,24 0.73 (0.36-1.52) 
5-9 298 55 19.8 (18.8-20.8) 1.15 (0.68-1.94) 0,59 1.23 (0.72-2.12) 
10-14 216 84 38.9 (37.9-39.9) 2.97 (1.77-4.99) <0,0001  3.11 (1.81-5.30) 
15-19 143 71 49.7 (48.5-50.9) 4.60 (2.66-7.97) <0,0001  4.16 (2.35-7.35) 
>20 603 535 88.7 (88.4-88.9) 36.7 (22.1-61.0) <0,0001  33.6 (19.9-57.6) 
Gender      
female  749  389 51.9 (51.4-52.4) 1    1 0.87
male 761 398 52.3 (51.8-52.8)  1.01 (0.82-1.24) 0.88 0.98 (0.75-1.27) 
Past hepatitis      
no  1,184 587 49.6 (48.6-50.6) 1  1 
yes 268 186 69.4 (68.7-70.1) 2.31 (1.74-3.06) <0.001   1.06 (0.75-1.49) 0.74
Hep B vaccine      
no 343 248 72.3 (71.7-72.9) 1  1 0.005
yes 1,113 514 46.2 (45.8-46.6) 0.33 (0.25-0.43) <0.001 0.62 (0.44-0.87) 
Anti-HBC: antibody against hepatitis B core antigen; n: number; %: percentage; 95% CI: 95% confidence interval; Hep B vaccine: hepatitis B vaccine. 
*Adjusted for the variables in Table 1; p-value: statistical significance;**Chi-square for linear trend; OR: odds ratio. 
TABLE 2 - Hepatitis B surface antigen (HBsAg reactive) prevalence and associated variables, Rural Lábrea municipality, Western Amazon, Brazil, 2007.
 Subjects Positive subjects                                                                          Adjusted 
Variable (n) n % 95% CI Crude OR (95% CI) p-value          OR (95% CI)* p-value
Total sample 1,510 94 6.2 (5.2-7.6) — — — —
Age group      
<2 136 3 2.2 (0.54-3.86) 1   1  
3-4 114 1 0.9 (-0.92-2.72) 0.39 (0.40-3.82) 0,42 0.47 (0.48-4.62) <0.001**
5-9 298 12 4.0 (2.89-5.11) 1.86 (0.51-6.70) 0,34 1.83 (0.50-6.66) 
10-14 216 12 5.6 (4.31-6.89) 2.60 (0.72-9.41) 0,14 2.35 (0.64-8.61) 
15-19 143 5 3.5 (2.49-4.51) 1.60 (0.37-6.84) 0,52 1.21 (0.28-5.25) 
>20 603 61 10.1 (9.34-10.9) 4.98 (1.54-16.14) 0,007 2.88 (0.87-9.55) 
Gender      
female 749 49 6.5 (5.8-7.2)  1  1    
male 761 45 5.9 (5.2-6.6) 0.89 (0.59-1.36) 0,61 0.81 (0.52-1.25) 0.35
Past hepatitis      
no 1,184 37 4.8 (4.3 - 5.4)  1  1 
yes 268 37 13.8 (12.7-14.9) 3.17 (2.04-4.90) <0.001 2.44 (1.52-3.89) <0.001
Hep B vaccine      
no 343 41 12.0 (11.0-13.0)  1   1  
yes 1,113 49 4.4 (3.8 - 4.9) 0.33 (0.21-0.56) <0.001 0.43 (0.27-0.69) <0.001
HBsAg: hepatitis B surface antigen; n: number; %: percentage; 95% CI: 95% confidence interval; Hep B vaccine: hepatitis B vaccine. 
*Adjusted odds ratio for the variables in Table 2; p-value: statistical significance; **Chi-square for linear trend; OR: odds ratio.
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conducted after the introduction of an immunization program, 
which allowed us to measure the impact of HBV vaccination in this 
single region.
We examined the HBV prevalence, taking into account the 
presence of two specific serological markers. Because the presence of 
total antibodies against the core antigen (total anti-HBc) is a marker 
of past infection, it can measure the importance of the circulation 
of the virus but lacks the strength for inferences concerning clinical 
aspects and transmission. Nevertheless, the presence of HBsAg can 
identify the transmission scenario and potentially chronically ill 
individuals.
While studies worldwide have found important drops in the 
rates of past HBV infection, as shown by a study in the Colombian 
Amazon, where less than 10% of the population aged 5-9 years and 
around 25% of those 10 to 14 years showed positive, representing a 
reduction of 72 and 62%, respectively, after the introduction of the 
vaccine22. In contrast, our study described much higher figures among 
the same age groups: 19.8% and 38.9%, respectively. In addition, we 
reported rates close to 50% in a group of individuals who should have 
been immunized after these nineteen years; that is, those aged 15 to 
19 years, who belonged to the target population in the first five years 
of the introduction of the vaccine in the community.
Considering the rates of past infection reported before the 
introduction of the vaccine, which showed important variations (for 
example, from 15 to 32% for those up to five years old)23-24, the rate of 
less than 15% among those 3-4 years old reported in the present study 
suggests some impact of the vaccination program on new infections, 
especially among younger people. Still, we must be cautious with any 
conclusions because the majority of previous studies done in this 
region before the introduction of the HBV vaccine were analyses of 
non-probabilistic samples.
Our study was able to demonstrate that there has been an 
important circulation of the virus since very young ages among 
individuals who should have already been fully immunized. However, 
we may also stress the fact that the distribution of past infection was 
heterogeneous among the studied villages and that, in some villages, 
the whole studied population showed no contact with HBV.
Given that this heterogeneous pattern within villages has been 
described since the late 1960s5-6, HBV vaccination might have had 
little impact in changing the HBV epidemiology, which seems to have 
maintained its historical pattern. We believe that genetic factors25 and 
the vaccination program strategies’ failure to focus on risk groups may 
possibly explain some of these differences since the environmental 
and social economic conditions are very similar.
Unlike many other publications from former highly endemic 
countries describing a dramatic drop in the prevalence of HBV 
carriage after the introduction of the HBV vaccine in their 
national immunization programs17,26-28, we report an overall 
prevalence of HBV carriage identified only in highly endemic 
areas, possibly with no counterpart in the literature thus far in 
the post-vaccination era.
Chronic carriers were found in all age groups. Indeed, we 
were able to distinguish three different cohorts with indications of 
important transmission intensity among those who theoretically 
should be protected. Infection among those aged up to two years 
supports the possibility of vertical transmission, while the prevalence 
among children aged between three and ten years indicates potential 
horizontal transmission among young groups; within adolescents and 
young adults up to 19 years, it is possible that infection is due to sexual 
transmission. Since the virus circulates in all ages, the transmission 
is dependent on the type of risk factor present in each age cohort.
The prevalence and age distribution of HBeAg support the idea 
of important transmission among early ages because the presence of 
this serological marker indicates new infections, high viral load, and 
potential infectivity29.
Taking into account that the prevalence of HBsAg carriage 
reported in this region before the introduction of the vaccine13,24 
varied from 7% and 12%, there has been very little change in the 
epidemiological pattern of HBV distribution in this specific region 
from a hyperendemic situation to a highly to moderately endemic 
pattern. This is in contrast to the situation in Italy, where the 
prevalence of HBsAg dropped from 13% to less than 1% after twenty 
years of universal vaccination26, and in Taiwan, which expected 
an overall prevalence rate of HBsAg carriage of less than 0.01% 
in the year 201027. In the Colombian Amazon, the prevalence of 
HBsAg carriage among those 5-9 years old dropped from 9% to 2%, 
indicating a reduction of more than 70% after eight years of HBV 
vaccination22.
We do not need to go too far to find better results of the HVB 
vaccination program in an Amazonian community. A study done in 
the year 2000 in the urban area of Lábrea not only demonstrated a 
low prevalence of HBV carriage among those born in the urban area 
and no carriers before adolescence but also suggested that the real 
problem with HBV infection would be in rural sites19.
Risk factors such as increasing age and past history of clinical 
hepatitis were strong predictors of HBV carriage even after those 
nineteen years, suggesting once again that the HBV vaccination 
program may have had little impact in changing the HBV 
epidemiology and on the aetiology of acute and chronic hepatitis 
in this region. Nevertheless, the hepatitis B vaccine has been shown 
to be an important protection against HBV, with those vaccinated 
having almost half the risk of infection and carriage of those not 
vaccinated, reinforcing the notion that the high figures we are 
describing may be related to a failure to deliver the vaccine to the 
population at risk.
In conclusion, our study demonstrates that HBV continues to be 
an important public health issue in the Amazon region and that the 
implementation of the HBV vaccination program in the rural area of 
Lábrea should have had a much stronger impact on HBV infection 
and carriage, as observed elsewhere. Vaccination strategies should 
focus on specific risk groups, such as infants born to a HBsAg-positive 
mother and adolescents. It seems that those who escape the vaccine 
intervention are responsible for keeping the prevalence rates of HBV 
infection and carriage among the highest still reported.
Hepatitis B vaccination programs are basically implemented to 
reduce HBsAg carriage because this marker of current infection is 
strongly correlated to chronic liver diseases, such as cirrhosis and 
liver cancer. The Amazonian environment may present operational 
difficulties for the delivery of any vaccine, mainly because of scarcity 
of resources and inadequate infrastructure. If we can extrapolate 
these findings to other rural areas in the Brazilian Western Amazon, 
we can predict that the sources of chronic infected patients remain 
a challenge. Future studies are needed regarding clinical aspects, 
molecular epidemiology, and surveillance of acute cases.
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